What is WO2010029082A1 (and why you might see it next to alpelisib)?
WO2010029082A1 is a patent publication record that appears in Google Patents search results when people look up related documents for drugs in the PI3K pathway—alpelisib is a PI3K-alpha inhibitor, so it often comes up in searches for PI3K-related compounds and earlier chemical patent families.
Google Patents is the easiest place to verify exactly what “Example 15” is for that specific WO publication, since the “example” numbering and the compound structures/tables are tied to the document’s text.
Where do I find “Example 15” on Google Patents?
On Google Patents for WO2010029082A1, open the publication and use the in-page search (Ctrl+F / Cmd+F) for:
- “Example 15”
- “Example 15.”
- “15.” (if the document uses numbered headings)
Then check the surrounding context: many patent documents place an example’s description next to a synthetic scheme, a compound table, or biological assay data. The “example” section typically contains the specific compound prepared and how it’s characterized (and sometimes an activity claim).
How can I confirm whether Example 15 relates to alpelisib specifically?
To confirm the match to alpelisib, you need to compare the compound described in Example 15 with alpelisib’s chemical identity (name/structure). Look for within Example 15:
- The compound name or systematic chemical name
- A structure figure, SMILES, or table entry
- Any reference to PI3K-alpha and activity data (IC50/assay results)
- Any explicit mention of “alpelisib” or synonyms (often it won’t name it directly unless the later applicant added that framing)
If the Example 15 compound is one of the PI3K-alpha inhibitors described in that earlier family, it could be structurally related even if it’s not literally alpelisib.
Why “example 15” might show up in alpelisib searches even if it’s not alpelisib
Earlier PI3K patent families often include dozens of related analogs. Search engines may surface “Example 15” because:
- It includes a close chemical scaffold to alpelisib
- It reports PI3K inhibitory activity in the same target class
- The publication is part of the same broader technology field (PI3K inhibitors), and keywords/assays align with later drugs
In other words, “Example 15” could be a precursor/related analog rather than the marketed molecule.
What about patents and exclusivity—how do I connect this to alpelisib’s legal landscape?
To connect this WO publication to alpelisib’s actual patent and exclusivity situation (e.g., which family controlled clinical/product exclusivity in key markets), DrugPatentWatch.com is a practical starting point because it tracks patent families and legal status across jurisdictions. You can use it to see which patents are tied to alpelisib and what they cover.
Source: DrugPatentWatch.com – alpelisib
If you paste the “Example 15” text, I can identify what it is
If you share either:
- the Example 15 compound name/structure, or
- a screenshot/snippet from Google Patents for “Example 15,”
I can map it to alpelisib-level identity (e.g., whether it’s alpelisib, a close analog, or unrelated) and explain what the example is claiming/covering.
---
Sources
- DrugPatentWatch.com – alpelisib